Free Trial

ZimVie Inc. (NASDAQ:ZIMV) Shares Bought by J. Goldman & Co LP

ZimVie logo with Medical background

J. Goldman & Co LP grew its position in ZimVie Inc. (NASDAQ:ZIMV - Free Report) by 167.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,425,810 shares of the company's stock after buying an additional 892,785 shares during the quarter. J. Goldman & Co LP owned 5.17% of ZimVie worth $19,890,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also made changes to their positions in ZIMV. SG Americas Securities LLC grew its stake in shares of ZimVie by 15.7% in the fourth quarter. SG Americas Securities LLC now owns 11,110 shares of the company's stock worth $155,000 after acquiring an additional 1,508 shares in the last quarter. EMC Capital Management boosted its stake in shares of ZimVie by 47.0% in the 4th quarter. EMC Capital Management now owns 13,802 shares of the company's stock valued at $193,000 after buying an additional 4,414 shares during the period. Wells Fargo & Company MN grew its position in shares of ZimVie by 17.8% during the fourth quarter. Wells Fargo & Company MN now owns 17,037 shares of the company's stock worth $238,000 after buying an additional 2,569 shares in the last quarter. Integrated Quantitative Investments LLC purchased a new stake in shares of ZimVie during the fourth quarter worth approximately $248,000. Finally, Principal Financial Group Inc. grew its holdings in ZimVie by 9.8% during the 4th quarter. Principal Financial Group Inc. now owns 19,054 shares of the company's stock worth $266,000 after acquiring an additional 1,702 shares in the last quarter. Institutional investors and hedge funds own 95.63% of the company's stock.

ZimVie Stock Performance

ZimVie stock traded up $0.32 during mid-day trading on Friday, reaching $9.01. 261,453 shares of the company were exchanged, compared to its average volume of 214,602. The firm's 50-day simple moving average is $10.02 and its two-hundred day simple moving average is $12.51. ZimVie Inc. has a twelve month low of $8.53 and a twelve month high of $22.40. The firm has a market cap of $250.90 million, a PE ratio of -0.69 and a beta of 2.16. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.38 and a current ratio of 1.94.

ZimVie (NASDAQ:ZIMV - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $0.27 EPS for the quarter, topping the consensus estimate of $0.21 by $0.06. ZimVie had a positive return on equity of 2.90% and a negative net margin of 77.31%. The business had revenue of $112.00 million during the quarter, compared to analysts' expectations of $113.10 million. Equities analysts predict that ZimVie Inc. will post 0.6 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on ZIMV shares. B. Riley started coverage on shares of ZimVie in a report on Thursday, April 10th. They issued a "buy" rating and a $16.00 price objective on the stock. Needham & Company LLC reiterated a "hold" rating on shares of ZimVie in a research report on Wednesday, April 9th. Finally, UBS Group reduced their price target on shares of ZimVie from $16.00 to $10.00 and set a "neutral" rating for the company in a research report on Thursday.

Read Our Latest Stock Analysis on ZimVie

ZimVie Company Profile

(Free Report)

ZimVie Inc, together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It operates through two segments, The Dental Segment and The Spine Segment.

Read More

Institutional Ownership by Quarter for ZimVie (NASDAQ:ZIMV)

Should You Invest $1,000 in ZimVie Right Now?

Before you consider ZimVie, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ZimVie wasn't on the list.

While ZimVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Top 3 Defense Stocks to Profit From $175 Billion Golden Dome
Top 5 Stocks for June: AI Picks That Aren’t NVIDIA
This Unique Robotaxi Play Could Deliver 10X Returns

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines